

SUPPLEMENTARY MATERIAL

Sociodemographic and spending characteristics of Medicare beneficiaries taking prescription drugs subject to price negotiations

Irina C. Odouard, MPH; Gerard Anderson, PhD; G. Caleb Alexander, MD, MS; Jeromie Ballreich, PhD, MHS

SUPPLEMENTARY TABLE 1 Medicare Part D Prescription Drugs Facing Price Negotiations in 2026 Under the Inflation Reduction Act

Supplementary Table 1. Medicare Part D prescription drugs facing price negotiations in 2026 under the Inflation Reduction Act.

Drug(brand name)	Therapeutic Class	Primary indication(s)	Product Type	Approval year
Apixaban (Eliquis)	Factor Xa inhibitor	Blood clots	Small molecule	2012
Rivaroxaban (Xarelto)	Factor Xa inhibitor	Blood clots, coronary artery disease	Small molecule	2011
Sitagliptin phosphate (Januvia)	DPP-4 inhibitor	Type 2 diabetes	Small molecule	2006
Insulin aspart (Fiasp; Fiasp FlexTouch; Fiasp PenFill; NovoLog; NovoLog FlexPen; NovoLog PenFill)	Human insulin	Type 2 diabetes	Biologic	2000
Ibrutinib (Imbruvica)	Kinase inhibitor	Blood cancer	Small molecule	2013
Empagliflozin (Jardiance)	SGLT2 inhibitor	Type 2 diabetes, heart failure	Small molecule	2014
Etanercept (Enbrel)	TNF blocker	Autoimmune conditions	Biologic	1998
Sacubitril and valsartan (Entresto)	Nepriylsin inhibitor and angiotensin II receptor blocker	Heart failure	Small molecule	2015
Ustekinumab (Stelara)	IL-12 and -23 antagonist	Autoimmune conditions	Biologic	2009
Dapagliflozin (Farxiga)	SGLT2 inhibitor	Chronic kidney disease, heart failure, type 2 diabetes	Small molecule	2014

Source: Product Prescribing Information.